AbbVie updates 2024 EPS guidance after incurring $164M IPR&D expense in Q1

AbbVie Inc.

2024-Q1 EPS reported $0.77 revenue$12,310,000,000

Acquired IPR&D and milestones expense of $164M pre-tax ($0.08 per share) recorded in Q1 2024.
Q1 2024 adjusted diluted EPS guidance revised to $2.18-$2.22 from $2.26-$2.30 previously.
Full-year 2024 adjusted diluted EPS guidance revised to $10.97-$11.17 from $11.05-$11.25.
Future IPR&D and milestones expense excluded from guidance due to unpredictable deal timing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.